Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics
Mehdi Hamadani(Medical College of Wisconsin), Peter Dreger(Heidelberg University), Norbert Schmitz(University Hospital Münster), Mutlu Arat(Istanbul Florence Nightingale Hospital), Silvia Montoto(Queen Mary University of London), Jasmine Zain(City of Hope), Farhad Khimani(Moffitt Cancer Center), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Luca Castagna(Humanitas University), Didier Blaise(Institut Paoli-Calmettes), Amanda F. Cashen(Washington University in St. Louis), Alex F. Herrera(City of Hope), Craig S. Sauter(Memorial Sloan Kettering Cancer Center), Mi Kwon(Hospital General Universitario Gregorio Marañón), Mazyar Shadman(University of Washington), Maud Ngoya, Paolo Corradini(Gruppo di Ricerca Geriatrica), Hervé Finel, Sascha Dietrich(European Molecular Biology Organization), Qaiser Bashir(The University of Texas MD Anderson Cancer Center), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Rocco Pastano(European Institute of Oncology), Yue Chen(Peking University), Ariane Boumendil(Inserm), Bertram Glaß(Helios Hospital Berlin-Buch), Carlos Litovich(Medical College of Wisconsin)
Cited by 47
Related Papers
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782